Clinical trials: Metastatic Gastrointestinal Carcinoid Tumor
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine…
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00027638
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse.
- Conditions
- Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor
- Trial name
- NCT01841736
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 423 sites in United States, Canada
- Volunteers
- 171 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoid Syndrome, Carcinoid Tumor
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors.
- Conditions
- Carcinoid Syndrome, Carcinoid Tumor, Digestive System Neuroendocrine Tumor G1, Metastatic Carcinoid Tumor
- Trial name
- NCT04993261
- Testing
- Dual-Energy Computed Tomography
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumor, Islet Cell Tumor
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.
- Trial name
- NCT00434109
- Testing
- Sunitinib malate, Hepatic Artery Embolizations
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Gastrinoma, Glucagonoma
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00075439
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's…
- Trial name
- NCT00003439
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1…
- Conditions
- Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT06016855
- Testing
- Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1
- Trial name
- NCT00454363
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Appendix Cancer, Appendiceal Cancer
Genetics of Appendix Cancer Study
The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years.
- Conditions
- Appendix Cancer, Appendiceal Cancer, Appendiceal Neoplasms, Appendiceal Mucinous Neoplasm
- Trial name
- GAP (NCT05734430)
- Testing
- Genetic profiling, Retrospective tissue procurement
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Andreana Holowatyj, PhD, MSCI
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Neuroendocrine Tumors
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
This study will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic pancreatic neuroendocrine tumors (PNETs) or or…
- Trial name
- GI-NETorPNET (NCT02132468)
- Testing
- fosbretabulin tromethamine
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mateon Therapeutics
Adult Solid Neoplasm, Lung Carcinoid Tumor
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of trebananib and temsirolimus when given together in treating patients with solid tumors that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Solid Neoplasm, Lung Carcinoid Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01548482
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus
- Where
- 3 sites in Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Head and Neck Cancer
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition
- Trial name
- NCT00900419
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis, sputum cytology
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- University of Colorado, Denver
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
This phase I trial studies the side effects and best dose of cixutumumab when given together with everolimus and octreotide acetate in treating patients with advanced low- or intermediate-grade neuroendocrine cancer.
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma
- Trial name
- NCT01204476
- Testing
- Cixutumumab, Everolimus, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Gastrinoma, Glucagonoma
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00084461
- Testing
- romidepsin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)